Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07094048 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Study acronym: CHUQUL_HO001
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 1 to 2v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v4
  3. Start date: Dec 2025 to Jan 5, 2026v3
  4. Start date: Sep 2025 to Dec 2025v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Trial Details
NCT Number NCT07094048
Lead Sponsor CHU de Quebec-Universite Laval
Conditions
(from sponsor)		 Multiple Myeloma Refractory, Relapsed Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov